NO984415D0 - Peptider med antiproliferative egenskaper - Google Patents

Peptider med antiproliferative egenskaper

Info

Publication number
NO984415D0
NO984415D0 NO984415A NO984415A NO984415D0 NO 984415 D0 NO984415 D0 NO 984415D0 NO 984415 A NO984415 A NO 984415A NO 984415 A NO984415 A NO 984415A NO 984415 D0 NO984415 D0 NO 984415D0
Authority
NO
Norway
Prior art keywords
peptides
nucleic acids
growth factor
relates
segments
Prior art date
Application number
NO984415A
Other languages
English (en)
Other versions
NO984415L (no
Inventor
Razvan T Radulescu
Original Assignee
Razvan T Radulescu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19653445A external-priority patent/DE19653445C1/de
Application filed by Razvan T Radulescu filed Critical Razvan T Radulescu
Publication of NO984415D0 publication Critical patent/NO984415D0/no
Publication of NO984415L publication Critical patent/NO984415L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
NO984415A 1996-03-26 1998-09-22 Peptider med antiproliferative egenskaper NO984415L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19611939 1996-03-26
DE19653445A DE19653445C1 (de) 1996-03-26 1996-12-20 Peptide mit antineoplastischen Eigenschaften
PCT/DE1997/000643 WO1997035873A2 (de) 1996-03-26 1997-03-26 Peptide mit antiproliferativen eigenschaften

Publications (2)

Publication Number Publication Date
NO984415D0 true NO984415D0 (no) 1998-09-22
NO984415L NO984415L (no) 1998-09-22

Family

ID=26024147

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984415A NO984415L (no) 1996-03-26 1998-09-22 Peptider med antiproliferative egenskaper

Country Status (10)

Country Link
US (1) US6660830B1 (no)
EP (1) EP0892811B1 (no)
JP (1) JP2001508643A (no)
CN (1) CN1214694A (no)
AT (1) ATE229977T1 (no)
AU (1) AU727662B2 (no)
BR (1) BR9711795A (no)
CA (1) CA2251691A1 (no)
NO (1) NO984415L (no)
WO (1) WO1997035873A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997660A (zh) * 2004-04-21 2007-07-11 芝加哥大学 肌球蛋白轻链激酶抑制剂及其使用
US7947645B2 (en) * 2004-09-02 2011-05-24 Cognosci, Inc. APO E analogs and methods for their use
EP1957045A2 (en) * 2005-03-14 2008-08-20 Board of Regents, The University of Texas System Bioactive fus1 peptides and nanoprticle-polypeptide complexes
KR100729830B1 (ko) * 2005-03-24 2007-06-19 바이오스펙트럼 주식회사 페너트라틴을 이용하여 단백질의 세포투과를 증진시키는대장균용발현벡터
US9243035B2 (en) * 2013-11-26 2016-01-26 Nymox Corporation Peptides effective in the treatment of conditions requiring the removal or destruction of cells
US10513711B2 (en) 2014-08-13 2019-12-24 Dupont Us Holding, Llc Genetic targeting in non-conventional yeast using an RNA-guided endonuclease
AU2015343307B2 (en) 2014-11-06 2021-05-20 Iff Us Holding, Llc Peptide-mediated delivery of RNA-guided endonuclease into cells
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
DK3362560T3 (da) 2015-10-12 2022-11-07 Dupont Us Holding Llc Beskyttede dna-templater til genmodificering og forøget homolog rekombination i celler og fremgangsmåder til anvendelse
KR20180059535A (ko) 2015-10-20 2018-06-04 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 마커-프리 게놈 변형을 위한 방법 및 조성물
BR112018007796A2 (pt) 2015-11-06 2018-10-30 Du Pont plantas de soja, partes de plantas de soja ou sementes de soja, método para selecionar uma célula de soja, métodos de seleção de uma célula de soja e de produção de um locus e molécula de ácido nucleico
US20190161742A1 (en) 2016-03-11 2019-05-30 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
MX2018014993A (es) 2016-06-14 2019-09-06 Pioneer Hi Bred Int Uso de endonucleasa cpf1 para modificaciones de genoma de planta.
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US20190100745A1 (en) 2016-06-20 2019-04-04 Pioneer Hi-Bred International, Inc. Novel cas systems and methods of use
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
WO2018129440A1 (en) 2017-01-09 2018-07-12 University Of Massachusetts Complexes for gene deletion and editing
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
AU2018386002A1 (en) 2017-12-15 2020-05-28 Danisco Us Inc CAS9 variants and methods of use
US20220162621A1 (en) 2019-04-05 2022-05-26 Danisco Us Inc Methods For Polynucleotide Integration Into The Genome Of Bacillus Using Dual Circular Recombinant DNA Constructs And Compositions Thereof
JP2022526982A (ja) 2019-04-05 2022-05-27 ダニスコ・ユーエス・インク 線状組換えＤＮＡコンストラクトを使用してバチルス（Ｂａｃｉｌｌｕｓ）のゲノムにドナーＤＮＡ配列を組み込むための方法及びその組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851991A (en) * 1987-08-31 1998-12-22 The Regents Of The University Of California Therapeutic use of the retinoblastoma susceptibility gene product
EP0398955B1 (en) * 1988-01-21 1998-07-08 MASSACHUSETTS EYE & EAR INFIRMARY Diagnosis of retinoblastoma
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
IL106760A (en) * 1992-08-25 1999-12-31 Miles Inc Nuclear Acid Protein Hybrid Structure for Transferring Nucleic Acid from External Source to Cell and Target Nucleus
DE4237129A1 (de) * 1992-11-03 1994-05-05 Radulescu Razvan Tudor Dr Med Anwendung der Komplementärpeptid-Theorie in der Onkologie/Kartiologie: 1. VPH = NH¶2¶-len alphaN-Me-Phe Tyr Lys alphaN-Me-Lys Val D-Tyr-COOH 2. Kalziumantagonist auf der Basis eines Komplementärpeptides zur Calmodulinbindungsstelle 3.hSNI¶B¶¶1¶¶6¶¶-¶¶2¶¶1¶[3'->5'] = NH¶2¶-Len Pro Thr His Asp Ala-COOH
US5625031A (en) * 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
EP0685493A1 (en) * 1994-06-01 1995-12-06 CANJI, Inc. Tumor suppressor fusion proteins
AU2773695A (en) * 1994-06-13 1996-01-05 Vanderbilt University Compositions for and methods of enhancing delivery of nucleic acids to cells
US5573925A (en) * 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
DE19526174C2 (de) * 1995-07-18 1998-02-26 Friedhelm Prof Dr Herrmann Mittel gegen Tumorwachstum

Also Published As

Publication number Publication date
BR9711795A (pt) 2000-06-06
AU2633497A (en) 1997-10-17
US6660830B1 (en) 2003-12-09
WO1997035873A3 (de) 1997-12-31
ATE229977T1 (de) 2003-01-15
EP0892811A2 (de) 1999-01-27
CA2251691A1 (en) 1997-10-02
WO1997035873A2 (de) 1997-10-02
AU727662B2 (en) 2000-12-21
JP2001508643A (ja) 2001-07-03
NO984415L (no) 1998-09-22
CN1214694A (zh) 1999-04-21
EP0892811B1 (de) 2002-12-18

Similar Documents

Publication Publication Date Title
NO984415L (no) Peptider med antiproliferative egenskaper
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DK0814827T3 (da) Karendotel-vækstfaktor-B
MX344216B (es) Productos geneticos expresados de forma diferencial en tumores y su uso.
EP1067182A3 (en) Secretory protein or membrane protein
RU95115239A (ru) Аналог эритропоэтина
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
DE60132075D1 (de) Wnt-1 verwandte polypeptide und dafür kodierende nukleinsäuren
DE69637148D1 (de) Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
ATE380867T1 (de) Lactoferrinrezeptorgen von moraxella
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
SE9602496D0 (sv) Method and means for producing a fibrinogen binding protein and its use in biotechnology
FR2744455B1 (fr) Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications
EP0815240A4 (en) NOVEL KINASE-LIKE CYCLINE-LIKE PROTEINS AND METHODS OF APPLICATION THEREOF
CY1105226T1 (el) Dna και πολυπεπτιδια il-1 εψιλον ανθρωπου
ES2191033T3 (es) Alergenos recombinantes de cladosporium herbarum.
EA199800862A1 (ru) Пептиды, обладающие антипролиферативными свойствами

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application